| Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation BA Hilliard, N Mason, L Xu, J Sun, SE Lamhamedi-Cherradi, HC Liou, ... The Journal of clinical investigation 110 (6), 843-850, 2002 | 277 | 2002 |
| Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine … NJ Mason, JS Gnanandarajah, JB Engiles, F Gray, D Laughlin, ... Clinical Cancer Research 22 (17), 4380-4390, 2016 | 185 | 2016 |
| Veterinary cooperative oncology group—common terminology criteria for adverse events (VCOG‐CTCAE v2) following investigational therapy in dogs and cats AK LeBlanc, M Atherton, RT Bentley, CE Boudreau, JH Burton, KM Curran, ... Veterinary and comparative oncology 19 (2), 311-352, 2021 | 170 | 2021 |
| Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial PM Bath, P Scutt, CS Anderson, JP Appleton, E Berge, L Cala, M Dixon, ... The Lancet 393 (10175), 1009-1020, 2019 | 164 | 2019 |
| Checkpoint blockade reverses anergy in IL-13Rα2 humanized scFv-based CAR T cells to treat murine and canine gliomas Y Yin, AC Boesteanu, ZA Binder, C Xu, RA Reid, JL Rodriguez, DR Cook, ... Molecular Therapy-Oncolytics 11, 20-38, 2018 | 150 | 2018 |
| Cutting edge: identification of c-Rel-dependent and-independent pathways of IL-12 production during infectious and inflammatory stimuli N Mason, J Aliberti, JC Caamano, HC Liou, CA Hunter The Journal of Immunology 168 (6), 2590-2594, 2002 | 132 | 2002 |
| Feasibility and safety of RNA-transfected CD20-specific chimeric antigen receptor T cells in dogs with spontaneous B cell lymphoma MK Panjwani, JB Smith, K Schutsky, J Gnanandarajah, CM O'connor, ... Molecular Therapy 24 (9), 1602-1614, 2016 | 128 | 2016 |
| Differential requirement for NF-κB family members in control of helminth infection and intestinal inflammation D Artis, S Shapira, N Mason, KM Speirs, M Goldschmidt, J Caamaño, ... The Journal of Immunology 169 (8), 4481-4487, 2002 | 115 | 2002 |
| Perspectives from man’s best friend: National Academy of Medicine’s Workshop on Comparative Oncology AK LeBlanc, M Breen, P Choyke, M Dewhirst, TM Fan, DL Gustafson, ... Science translational medicine 8 (324), 324ps5-324ps5, 2016 | 106 | 2016 |
| Cyclophosphamide exerts no beneficial effect over prednisone alone in the initial treatment of acute immune‐mediated hemolytic anemia in dogs: a randomized controlled clinical … N Mason, D Duval, FS Shofer, U Giger Journal of veterinary internal medicine 17 (2), 206-212, 2003 | 97 | 2003 |
| Companion animals in comparative oncology: One Medicine in action OA Garden, SW Volk, NJ Mason, JA Perry The Veterinary Journal 240, 6-13, 2018 | 88 | 2018 |
| New lessons from old pathogens: what parasitic infections have taught us about the role of nuclear factor‐κB in the regulation of immunity NJ Mason, D Artis, CA Hunter Immunological reviews 201 (1), 48-56, 2004 | 88 | 2004 |
| Opposing roles of NF-κB family members in the regulation of NK cell proliferation and production of IFN-γ CM Tato, N Mason, D Artis, S Shapira, JC Caamano, JH Bream, HC Liou, ... International immunology 18 (4), 505-513, 2006 | 82 | 2006 |
| T cell-intrinsic expression of c-Rel regulates Th1 cell responses essential for resistance to Toxoplasma gondii NJ Mason, HC Liou, CA Hunter The Journal of Immunology 172 (6), 3704-3711, 2004 | 82 | 2004 |
| TRAF6-dependent mitogen-activated protein kinase activation differentially regulates the production of interleukin-12 by macrophages in response to Toxoplasma gondii NJ Mason, J Fiore, T Kobayashi, KS Masek, Y Choi, CA Hunter Infection and immunity 72 (10), 5662-5667, 2004 | 81 | 2004 |
| A role for inducible costimulator protein in the CD28-independent mechanism of resistance to Toxoplasma gondii EN Villegas, LA Lieberman, N Mason, SL Blass, VP Zediak, R Peach, ... The Journal of Immunology 169 (2), 937-943, 2002 | 79 | 2002 |
| CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma KU Sorenmo, E Krick, CM Coughlin, B Overley, TP Gregor, ... PloS one 6 (8), e24167, 2011 | 77 | 2011 |
| Actionable mutations in canine hemangiosarcoma G Wang, M Wu, MA Maloneyhuss, J Wojcik, AC Durham, NJ Mason, ... PloS one 12 (11), e0188667, 2017 | 69 | 2017 |
| NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma A Gaurnier-Hausser, R Patel, AS Baldwin, MJ May, NJ Mason Clinical Cancer Research 17 (14), 4661-4671, 2011 | 67 | 2011 |
| A phase I clinical trial of systemically delivered NEMO binding domain peptide in dogs with spontaneous activated B-cell like diffuse large B-cell lymphoma G Habineza Ndikuyeze, A Gaurnier-Hausser, R Patel, AS Baldwin, ... PloS one 9 (5), e95404, 2014 | 55 | 2014 |
